Could Affymetrix Be Next Takeover in BioHealth? (AFFX, CALP, LIFE, QGEN)
Everyone wants to know which stocks in biotech and medical technology will be the next buyout target. It is rare that research reports or interviews from traditional brokerage firms point out an...
View ArticleBioHealth IPO Focus: Tengion, Organ Replacements (TNGN)
If you have heard horror stories about real human kidney theft, that may be a thing of the past. If this actually works. An IPO filing this week revealed a rather interesting company that we will...
View ArticleQuest For 10-Baggers in BioHealth in 2010 (JAZZ, TRGT, VNDA, DNDN, HGSI,...
If one thing was noticed in biotech stocks, or BioHealth stocks as we often say, it was that investors, traders, and speculators all piled into the chase for the next ten-bagger late in the year. When...
View ArticleClik here to view.
Top 2010 Established Biotech Stock Picks for Upside (MNKD, THRX, DNDN, INCY,...
BioHealthInvestor.com wanted to put together a list of key biotech and BioHealth-related stocks that had the most upside for 2010 according to consensus analyst price targets. This is of course no...
View ArticleAn Option Trader’s Take on Human Genome Sciences (HGSI)
Human Genome Sciences (NASDAQ: HGSI) has become a one of the biggest and widespread stocks literally out of the blue over the last year. This company went from what was originally a genomics stock...
View ArticleClik here to view.
Big Biotechs With The Most Upside for 2011 (AMGN, GILD, CELG, HGSI, DNDN,...
Bioheath Investor is creating some ongoing outlook pieces as 2010 ends so we have an outline of what to expect for 2011. We have already given the “Best of Big Biotech in 2010″ and now we want to...
View ArticleBenlysta Approval Cheat Sheet: What You Need to Know (HGSI, GSK)
It is official… The FDA has approved Benlysta as the first new drug regimen for systemic lupus in over 50 years. Human Genome Sciences, Inc. (NASDAQ: HGSI) and partner GlaxoSmithKline plc (NYSE: GSK)...
View ArticleWhy Celera’s Buyout Makes Sense (CRA, DGX, HGSI, AFFX, GHDX, GNOM, ROSG, HLCS)
If you would have said ten years ago that Celera Corporation (NASDAQ: CRA) would be acquired by Quest Diagnostics Inc. (NYSE: DGX), most investors would have said that you were off your rocker. Celera...
View ArticleQuest for $1,000 Genome: Complete Genomics Raises Expansion Capital (GNOM)
COMPLETE GENOMICS, INC. (NASDAQ: GNOM) has filed to raise up to $75 million in cash in a public stock offering. The filing is for 4.5 million shares, or it would be 5.175 million shares if the...
View ArticleQuest+Celera… Value With Growth (DGX, CRA)
Quest Diagnostics Inc. (NYSE: DGX) is a stock we have recently screened out for value investors who are looking for exposure to healthcare and now in genomics. Some investors might not recognize the...
View Article
